Adherence of denosumab treatment for low bone mineral density in Japanese people living with HIV: a retrospective observational study

Table 2 Demographic and clinical characteristics of denosumab adherence versus non-adherence groups at 24 months (n = 28) ^a

Characteristics	Denosumab treatment adherence at 24 months		p-value ^c
Characteristics	Adherent group (n = 17) ^b	Non-adherent group (n = 11) ^b	p-value ^c
Age (years), median (IQR)	39.0 (36.0–43.3)	39.0 (34.0–45.0)	0.962
Gender, male, n (%)	15 (88.2)	10 (90.9)	1.000
BMI (kg/m²), median (IQR)	21.4 (19.2–24.7)	19.0 (18.6–20.7)	0.145
Current smoking, n (%)	6 (35.3)	6 (54.5)	0.441
Prior AIDS diagnosis, n (%)	4 (23.5)	6 (54.5)	0.125
Time since diagnosis HIV (years), median (IQR)	5 (1–10)	1 (0–4)	0.007
CD4 cell count (cells/µL), median (IQR)	534 (373–805)	355 (149–827)	0.158
Time on antiretroviral therapy (years), median (IQR)	4 (2–10)	1 (1–3)	0.005
Denosumab treatment initiated before the COVID-19 pandemic, n (%)	16 (94.1)	6 (54.5)	0.022

Abbreviations: AIDS acquired immunodeficiency syndrome, BMI body mass index, COVID-19 coronavirus disease 2019, HIV human immunodeficiency virus, IQR interquartile range
^a Data are expressed as numbers and frequencies (%) or median values with interquartile ranges (IQRs)
^b Adherence and persistence were evaluated for 24 months, excluding one case that did not reach 24 months after the commencement of denosumab treatment
^c Fisher’s exact test was used for categorical data, and the Mann–Whitney U test was used for continuous data

ISSN: 2055-0294